Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Acta Neuropathol. 2018 Oct 31;137(1):71–88. doi: 10.1007/s00401-018-1925-9

Fig. 2. Immunohistochemical staining of MFSD8 in post-mortem tissue from FTLD patients carrying rare variants in MFSD8.

Fig. 2.

Representative images of immunostaining for MFSD8 in middle frontal gyrus of clinically normal, healthy controls (Controls, HC, panels A-E), FTLD patients carrying MFSD8 rare variants (Carriers, panels F-J), and patients with sporadic FTLD (Sporadic, panels K-O). All FTLD patients were matched for age, sex, and pathological diagnosis. Panels (D-E) are higher magnification images of MFSD8 immunoreactivity in neurons of the same healthy controls depicted in (A) and (C). MFSD8 Immunoreactivity in neurons (→) and astrocytes (►) are highlighted. See Table S4 for more details on specific pathological diagnoses and demographics of all FTLD patients and controls. All sections were counterstained with hematoxylin. Scale bar: 10 μm in (D-E), 20 μm in (O). TDP-B, TAR DNA-Binding Protein 43 - Type B; CBD, corticobasal degeneration; PSP, progressive supranuclear palsy.